Featuring perspectives from Dr Matthew D Galsky, including the following topics:

• HER2 alterations in urothelial cancer and current targeting approaches (0:00)
• Key findings supporting the use of trastuzumab deruxtecan for patients with HER2-overexpressing cancers as part of the Phase II DESTINY-PanTumor02 study (9:39)
• Targeting of HER2 using disitamab vedotin both as a monotherapy and in combination with other treatments (14:31)
• Case: A man in his late 70s with a history of non-muscle-invasive bladder cancer who develops HER2-positive lung metastases (28:57)
• Case: A man in his late 60s who receives disitamab vedotin for HER2 IHC 2+ metastatic urothelial cancer (36:25)
• Enfortumab vedotin and pembrolizumab as first-line or neoadjuvant therapy for targeting HER2-expressing cancers (39:34)
• Future direction of HER2-targeting therapies for urothelial bladder cancer (1:02:48)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Sunnie Kim, including the following topics:

• Year in Review: Novel Treatments and Strategies in Gastroesophageal Cancer — Dr Kim (0:00)
• Case: A man in his mid 50s with poorly differentiated mismatch repair-deficient advanced gastric cancer receives first-line nivolumab/ipilimumab (49:22)
• Case: A man in his early 70s with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma who experienced disease progression on FOLFOX/trastuzumab receives trastuzumab deruxtecan (54:48)
• Case: A man in his mid 60s with Stage IV, PD-L1-positive GEJ adenocarcinoma (58:11)
• Case: A man in his early 40s with metastatic CLDN18.2-positive gastric/GEJ adenocarcinoma receives zolbetuximab (1:01:10)

CME information and select publications

Featuring perspectives from Prof Eric Van Cutsem, including the following topics:

Immune Checkpoint Inhibitors in Localized Gastroesophageal (GE) Cancers

• Introduction (0:00)
• Case: A man in his mid 50s with localized, poorly differentiated signet ring, mismatch repair-deficient advanced gastric adenocarcinoma — Sunnie Kim, MD (3:39)

HER2-Positive GE Cancers

• Case: A man in his early 70s with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma and disease progression on FOLFOX/trastuzumab (PD-L1 CPS 0) — Dr Kim (19:22)

First-Line Treatment of Metastatic Gastric and GEJ Adenocarcinoma

• Case: A man in his early 40s who presents with metastatic GEJ adenocarcinoma (CLDN18.2-positive, PD-L1 CPS 2) in visceral crisis from lung metastases — Dr Kim (38:53)
• Case: A man in his mid 60s with metastatic GEJ adenocarcinoma (PD-L1 CPS 20) — Dr Kim (50:50)

CME information and select publications